# Bart Van Hooland

> Bart Van Hooland is a seed investor at Thia Ventures backing Biotechnology and Manufacturing. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Thia Ventures](https://shizune.co/investors/profile/thia-ventures)
- Location: Ghent, Belgium
- Total investments: 8
- Last investment: Feb 2025
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bart-van-hooland-23969a3/
- Website: https://x.com/hooleie

Bart Van Hooland is a Partner at Thia Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Manufacturing | 2 | 25% |
| Biopharma | 1 | 13% |
| CleanTech | 1 | 13% |
| Pharmaceutical | 1 | 13% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 38% |
| Series A | 1 | 13% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |
| Funding Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 25% |
| Denmark | 1 | 13% |
| United Kingdom | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| uFraction8 | uFraction8 provides scalable bioprocessing technology enabling biomass filtration, separation and dewatering, used with wide range of microbes like micro algae, yeast and bacteria, sorting biomass from culture medium with no harm and no flocculants unlike centrifuges, filters and membranes. | $4.3M |  | Feb 24, 2025 |  |
| EvodiaBio | EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region. | $7.2M | Series A | Jun 07, 2024 |  |
| Clever Carnivore | Clever Carnivore is a cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets. | $7M | Seed | Dec 04, 2023 |  |
| EvodiaBio | EvodiaBio is a bio-industrial firm that creates natural, sustainable scents for the food and beverage industries. Founded in 2021 and is based in Copenhagen, Capital Region. | $4.4M | Seed | Dec 20, 2022 |  |
| uFraction8 | uFraction8 provides scalable bioprocessing technology enabling biomass filtration, separation and dewatering, used with wide range of microbes like micro algae, yeast and bacteria, sorting biomass from culture medium with no harm and no flocculants unlike centrifuges, filters and membranes. | $3.4M | Seed | Jan 24, 2022 |  |
| Cyteir Therapeutics | Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $80M | Series C | Feb 11, 2021 |  |
| Cyteir Therapeutics | Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $40.2M | Series B | Oct 15, 2019 |  |
| Cyteir Therapeutics | Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $29M | Series B | Mar 08, 2018 |  |

8 of 8 investments shown.

## Co-investors
- [Lightstone Ventures](https://shizune.co/investors/profile/lightstone-ventures) — VC Fund, 3 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 3 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 3 deals together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 2 deals together
- [Newtree Impact](https://shizune.co/investors/profile/newtree-impact) — VC Fund, 2 deals together
- [Nordic Foodtech VC](https://shizune.co/investors/profile/nordic-foodtech-vc) — VC Fund, 2 deals together

## About Thia Ventures

VC Fund · Genève, Switzerland

Thia Ventures is an Early-stage investor in one of the most dynamic and essential fields of current human endeavor.

2 contacts available at Thia Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Bart Van Hooland | Managing Partner | https://shizune.co/investors/profile/bart-van-hooland-ab7a |
| Samuelle Thevenet | Chief Operating Officer | https://shizune.co/investors/profile/samuelle-thevenet |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Bart Van Hooland invest in?

Bart Van Hooland invests primarily in Biotechnology, Manufacturing and Biopharma startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bart Van Hooland last invest?

The most recent investment recorded for Bart Van Hooland closed in Feb 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co